Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.67 |
| ▸ | DRD4 | P21917 | 5/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335558 | 0.93 | CHRNA7 (0.58) | CHRNA7DRD4GRIN2BGRIN1POLB | |
| SCHEMBL4498788 | 0.93 | CHRNA7 (0.64) | CHRNA7DRD4GRIN2BGRIN1DDAH1 | |
| SCHEMBL5338493 | 0.90 | CHRNA7 (0.70) | CHRNA7DRD4GRIN2BGRIN1DDAH1 | |
| SCHEMBL14393788 | 0.88 | GRIN1 (0.70) | DRD4GRIN2BGRIN1HTTDRD2 | |
| SCHEMBL5334974 | 0.87 | CHRNA7 (0.57) | CHRNA7DRD4GRIN2BGRIN1POLB | |
| SCHEMBL5345348 | 0.85 | CHRNA7 (0.73) | CHRNA7DRD4GRIN2BGRIN1POLB | |
| SCHEMBL5333807 | 0.83 | LMNA (0.51) | CHRNA7DRD4GRIN2BGRIN1DRD2 | |
| SCHEMBL5333493 | 0.83 | CHRNA7 (0.60) | CHRNA7DRD4GRIN2BGRIN1POLB | |
| SCHEMBL5334025 | 0.81 | LMNA (0.50) | CHRNA7DRD4GRIN2BGRIN1DDAH1 | |
| SCHEMBL30117400 | 0.80 | DRD4 (0.67) | CHRNA7DRD4DDAH1POLBEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRNA7 13/4885DRD4 544/4885GRIN2B 257/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | CHRNA7 13/4885DRD4 544/4885GRIN2B 257/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | CHRNA7 13/4885DRD4 544/4885GRIN2B 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.